Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen

Thanks to the modern ARV regimens and the fact that the morbidity and mortality of metabolic syndrome increases with age, clinicians are continuously researching effective and safe antiretroviral regimens with low impact on the lipid profile. Doravirine (DOR) is the latest non-nucleoside reverse-tra...

Full description

Saved in:
Bibliographic Details
Published in:Viruses 2023-04, Vol.15 (5), p.1046
Main Authors: Iannone, Valentina, Passerotto, Rosa Anna, Lamanna, Francesco, Steiner, Rebecca Jo, Lombardi, Francesca, Salvo, Pierluigi Francesco, Dusina, Alex, Farinacci, Damiano, Borghetti, Alberto, Di Giambenedetto, Simona, Ciccullo, Arturo
Format: Article
Language:English
Subjects:
Anti-HIV Agents - therapeutic use
cardiovascular risk
Cholesterol
Clinical medicine
Communication
doravirine
Drug therapy
dyslipidemia
High density lipoprotein
HIV
HIV Infections - drug therapy
HIV patients
Human immunodeficiency virus
Humans
Immunology
Infections
Inflammation
Life expectancy
Lipid metabolism
Lipids
Lipoproteins
low density lipoprotein
Metabolic disorders
Metabolic syndrome
Metabolome
Morbidity
Mortality
NNRTI
Pharmacology, Experimental
Physiological aspects
Regression analysis
Retrospective Studies
Reverse Transcriptase Inhibitors - therapeutic use
Substance abuse treatment
Survival analysis
Treatment Outcome
Triglycerides
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thanks to the modern ARV regimens and the fact that the morbidity and mortality of metabolic syndrome increases with age, clinicians are continuously researching effective and safe antiretroviral regimens with low impact on the lipid profile. Doravirine (DOR) is the latest non-nucleoside reverse-transcriptase inhibitor (NNRTI) that shows long-term safety and tolerability and a favorable lipid profile. The aim of this study is to assess the impact of DOR-based three-drug regimens on the lipid profile in clinical practice. We retrospectively analyzed a cohort of 38 treatment-experienced, virologically suppressed people living with HIV (PLWH) switching to this regimen, following the eligibility criteria. We carried out comparison analysis of immunological and metabolic parameters between baseline and 48 weeks of follow up. In our cohort of treatment-experienced, virologically suppressed PLWH, three-drug regimens with DOR showed good efficacy and a positive profile on lipid metabolism at 48 weeks of follow up.
ISSN:1999-4915
1999-4915
DOI:10.3390/v15051046